Search

everythinglearnresearchcommunity

for

Search:↓

ASLAN004 was safe and well-tolerated, supporting further development for treating certain diseases.

Azathioprine can help with relapses and disability in NMOSD but has more side effects and needs more research.

Oral betamethasone mini-pulses effectively treat moderate to severe alopecia areata with manageable side effects.

Using Selenium Disulfide shampoo weekly helps prevent scalp dermatitis flare-ups.

Daclizumab may cause psoriasis-like skin problems in multiple sclerosis patients.

Azathioprine is the most continued treatment for chronic alopecia areata over a year, often with added low-dose prednisolone.

Mogamulizumab can cause hair loss and skin rashes.

Anti-IL-12/IL-23 antibody therapy effectively treats psoriasiform skin lesions in IBD patients.

All four treatments for early rheumatoid arthritis had similar safety profiles.

PX-12 may help treat psoriasis by blocking inflammation and cell death.

Methotrexate with corticosteroids can effectively treat severe alopecia areata but often requires long-term maintenance.

Squaric acid dibutylester can cause severe skin reactions in people with allergies.

Combining methotrexate and corticosteroids can effectively regrow hair in severe alopecia areata.

Apremilast showed mixed results for treating severe alopecia areata.

Teriflunomide effectively reduces relapse rates and disease progression in multiple sclerosis but is not safe for use during pregnancy.

Albendazole can cause hair loss, and piroxicam can cause fixed drug eruption.

A patient's grey hair regained color during treatment with adalimumab.

Tofacitinib improved ulcerative colitis, skin ulcers, and hair loss in a patient who didn't respond well to other treatments.

Adalimumab effectively stabilized severe folliculitis decalvans, preventing further hair loss and inflammation.

The combination therapy may be more effective for mild alopecia areata, especially in patients with allergies.

A patient with PPP had rare skin reactions to adalimumab, which improved after stopping smoking and continuing acitretin.

Systemic agents like cyclosporine, methotrexate, and acitretin help manage psoriasis but have significant side effects.

Low-dose methotrexate is generally safe but can cause mild to severe side effects, and folic acid can reduce these risks.

Nemolizumab improved both severe atopic dermatitis and alopecia areata in one patient.

IL-17 inhibitors are more effective than methotrexate in preventing psoriatic arthritis in psoriasis patients.

Methotrexate effectively managed SAPHO syndrome symptoms when other treatments failed.

Tacrolimus is a better option than cyclosporine due to fewer side effects.

Infliximab can cause SAPHO syndrome, which may improve with Spesolimab and methotrexate.

Monitor for early signs of myelosuppression, like hair loss, in patients on azathioprine to manage side effects.